To learn more about the natural history of low-grade non-Hodgkin's lymphoma, we have studied 83 patients in whom the advanced disease was initially managed without therapy. Actuarial survival was 82 per cent at 5 years and 73 per cent at 10 years. The median time until therapy was required was three years. Spontaneous regressions occurred in 19 untreated patients (23 per cent), including 30 per cent of patients with nodular, poorly differentiated lymphocytic lymphoma. Histologic transformation to an intermediate-grade or high-grade lymphoma occurred both before and after primary therapy. The actuarial risk of transformation among the initially untreated patients was similar to that in a group of patients treated at this institution immediately after diagnosis. Neither the time to histologic transformation nor the incidence of transformation was influenced by when therapy was started.
This article has been cited by other articles:
Sebban, C., Brice, P., Delarue, R., Haioun, C., Souleau, B., Mounier, N., Brousse, N., Feugier, P., Tilly, H., Solal-Celigny, P., Coiffier, B.
(2008). Impact of Rituximab and/or High-Dose Therapy With Autotransplant at Time of Relapse in Patients With Follicular Lymphoma: A GELA Study. JCO
26: 3614-3620
[Abstract][Full Text]
Krishnan, A., Nademanee, A., Fung, H. C., Raubitschek, A. A., Molina, A., Yamauchi, D., Rodriguez, R., Spielberger, R. T., Falk, P., Palmer, J. M., Forman, S. J.
(2008). Phase II Trial of a Transplantation Regimen of Yttrium-90 Ibritumomab Tiuxetan and High-Dose Chemotherapy in Patients With Non-Hodgkin's Lymphoma. JCO
26: 90-95
[Abstract][Full Text]
Tsimberidou, A. M., Wen, S., O'Brien, S., McLaughlin, P., Wierda, W. G., Ferrajoli, A., Faderl, S., Manning, J., Lerner, S., Mai, C. V., Rodriguez, A. M., Hess, M., Do, K.-A., Freireich, E. J., Kantarjian, H. M., Medeiros, L. J., Keating, M. J.
(2007). Assessment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma by Absolute Lymphocyte Counts in 2,126 Patients: 20 Years of Experience at The University of Texas M.D. Anderson Cancer Center. JCO
25: 4648-4656
[Abstract][Full Text]
Montoto, S., Davies, A. J., Matthews, J., Calaminici, M., Norton, A. J., Amess, J., Vinnicombe, S., Waters, R., Rohatiner, A. Z.S., Lister, T. A.
(2007). Risk and Clinical Implications of Transformation of Follicular Lymphoma to Diffuse Large B-Cell Lymphoma. JCO
25: 2426-2433
[Abstract][Full Text]
Gribben, J. G.
(2007). How I treat indolent lymphoma. Blood
109: 4617-4626
[Abstract][Full Text]
Glas, A. M., Knoops, L., Delahaye, L., Kersten, M. J., Kibbelaar, R. E., Wessels, L. A., van Laar, R., van Krieken, J. H. J.M., Baars, J. W., Raemaekers, J., Kluin, P. M., van 't Veer, L. J., de Jong, D.
(2007). Gene-Expression and Immunohistochemical Study of Specific T-Cell Subsets and Accessory Cell Types in the Transformation and Prognosis of Follicular Lymphoma. JCO
25: 390-398
[Abstract][Full Text]
Wahlin, B. E., Sander, B., Christensson, B., Kimby, E.
(2007). CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma. Clin. Cancer Res.
13: 388-397
[Abstract][Full Text]
Neelapu, S. S., Kwak, L. W.
(2007). Vaccine Therapy for B-Cell Lymphomas: Next-Generation Strategies. ASH Education Book
2007: 243-249
[Abstract][Full Text]
Lee, A. M., Clear, A. J., Calaminici, M., Davies, A. J., Jordan, S., MacDougall, F., Matthews, J., Norton, A. J., Gribben, J. G., Lister, T. A., Goff, L. K.
(2006). Number of CD4+ Cells and Location of Forkhead Box Protein P3-Positive Cells in Diagnostic Follicular Lymphoma Tissue Microarrays Correlates With Outcome. JCO
24: 5052-5059
[Abstract][Full Text]
Sebban, C., Mounier, N., Brousse, N., Belanger, C., Brice, P., Haioun, C., Tilly, H., Feugier, P., Bouabdallah, R., Doyen, C., Salles, G., Coiffier, B.
(2006). Standard chemotherapy with interferon compared with CHOP followed by high-dose therapy with autologous stem cell transplantation in untreated patients with advanced follicular lymphoma: the GELF-94 randomized study from the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood
108: 2540-2544
[Abstract][Full Text]
Brown, J. R.
(2006). In Reply. The Oncologist
11: 957-957
[Full Text]
Sjo, L D, Ralfkiaer, E, Juhl, B R, Prause, J U, Kivela, T, Auw-Haedrich, C, Bacin, F, Carrera, M, Coupland, S E, Delbosc, B, Ducrey, N, Kantelip, B, Kemeny, J L, Meyer, P, Sjo, N C, Heegaard, S
(2006). Primary lymphoma of the lacrimal sac: an EORTC ophthalmic oncology task force study. Br. J. Ophthalmol.
90: 1004-1009
[Abstract][Full Text]
Redfern, C. H., Guthrie, T. H., Bessudo, A., Densmore, J. J., Holman, P. R., Janakiraman, N., Leonard, J. P., Levy, R. L., Just, R. G., Smith, M. R., Rosenfelt, F. P., Wiernik, P. H., Carter, W. D., Gold, D. P., Melink, T. J., Gutheil, J. C., Bender, J. F.
(2006). Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin's Lymphoma Resulting in Durable Clinical Responses. JCO
24: 3107-3112
[Abstract][Full Text]
Huff, C. A., Matsui, W., Smith, B. D., Jones, R. J.
(2006). The paradox of response and survival in cancer therapeutics. Blood
107: 431-434
[Abstract][Full Text]
Tanimoto, K., Kaneko, A., Suzuki, S., Sekiguchi, N., Maruyama, D., Kim, S. W., Watanabe, T., Kobayashi, Y., Kagami, Y., Maeshima, A., Matsuno, Y., Tobinai, K.
(2006). Long-term follow-up results of no initial therapy for ocular adnexal MALT lymphoma. Ann Oncol
17: 135-140
[Abstract][Full Text]
Hiddemann, W., Kneba, M., Dreyling, M., Schmitz, N., Lengfelder, E., Schmits, R., Reiser, M., Metzner, B., Harder, H., Hegewisch-Becker, S., Fischer, T., Kropff, M., Reis, H.-E., Freund, M., Wormann, B., Fuchs, R., Planker, M., Schimke, J., Eimermacher, H., Trumper, L., Aldaoud, A., Parwaresch, R., Unterhalt, M.
(2005). Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood
106: 3725-3732
[Abstract][Full Text]
Farinha, P., Masoudi, H., Skinnider, B. F., Shumansky, K., Spinelli, J. J., Gill, K., Klasa, R., Voss, N., Connors, J. M., Gascoyne, R. D.
(2005). Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood
106: 2169-2174
[Abstract][Full Text]
Hiddemann, W., Buske, C., Dreyling, M., Weigert, O., Lenz, G., Forstpointner, R., Nickenig, C., Unterhalt, M.
(2005). Treatment Strategies in Follicular Lymphomas: Current Status and Future Perspectives. JCO
23: 6394-6399
[Abstract][Full Text]
Marcus, R., Imrie, K., Belch, A., Cunningham, D., Flores, E., Catalano, J., Solal-Celigny, P., Offner, F., Walewski, J., Raposo, J., Jack, A., Smith, P.
(2005). CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood
105: 1417-1423
[Abstract][Full Text]
Friedberg, J. W., Kim, H., McCauley, M., Hessel, E. M., Sims, P., Fisher, D. C., Nadler, L. M., Coffman, R. L., Freedman, A. S.
(2005). Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-{alpha}/{beta}-inducible gene expression, without significant toxicity. Blood
105: 489-495
[Abstract][Full Text]
Glas, A. M., Kersten, M. J., Delahaye, L. J. M. J., Witteveen, A. T., Kibbelaar, R. E., Velds, A., Wessels, L. F. A., Joosten, P., Kerkhoven, R. M., Bernards, R., van Krieken, J. H. J. M., Kluin, P. M., van't Veer, L. J., de Jong, D.
(2005). Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment. Blood
105: 301-307
[Abstract][Full Text]
Friedberg, J. W.
(2004). Radioimmunotherapy for Non-Hodgkin's Lymphoma. Clin. Cancer Res.
10: 7789-7791
[Full Text]
Dave, S. S., Wright, G., Tan, B., Rosenwald, A., Gascoyne, R. D., Chan, W. C., Fisher, R. I., Braziel, R. M., Rimsza, L. M., Grogan, T. M., Miller, T. P., LeBlanc, M., Greiner, T. C., Weisenburger, D. D., Lynch, J. C., Vose, J., Armitage, J. O., Smeland, E. B., Kvaloy, S., Holte, H., Delabie, J., Connors, J. M., Lansdorp, P. M., Ouyang, Q., Lister, T. A., Davies, A. J., Norton, A. J., Muller-Hermelink, H. K., Ott, G., Campo, E., Montserrat, E., Wilson, W. H., Jaffe, E. S., Simon, R., Yang, L., Powell, J., Zhao, H., Goldschmidt, N., Chiorazzi, M., Staudt, L. M.
(2004). Prediction of Survival in Follicular Lymphoma Based on Molecular Features of Tumor-Infiltrating Immune Cells. NEJM
351: 2159-2169
[Abstract][Full Text]
Forstpointner, R., Dreyling, M., Repp, R., Hermann, S., Hanel, A., Metzner, B., Pott, C., Hartmann, F., Rothmann, F., Rohrberg, R., Bock, H.-P., Wandt, H., Unterhalt, M., Hiddemann, W.
(2004). The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood
104: 3064-3071
[Abstract][Full Text]
Montoto, S., Lopez-Guillermo, A., Altes, A., Perea, G., Ferrer, A., Camos, M., Villela, L., Bosch, F., Esteve, J., Cervantes, F., Blade, J., Nomdedeu, B., Campo, E., Sierra, J., Montserrat, E.
(2004). Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression. Ann Oncol
15: 1484-1489
[Abstract][Full Text]
Zinzani, P. L., Pulsoni, A., Perrotti, A., Soverini, S., Zaja, F., De Renzo, A., Storti, S., Lauta, V. M., Guardigni, L., Gentilini, P., Tucci, A., Molinari, A. L., Gobbi, M., Falini, B., Fattori, P. P., Ciccone, F., Alinari, L., Martelli, M., Pileri, S., Tura, S., Baccarani, M.
(2004). Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab As Front-Line Treatment for Patients With Follicular Lymphoma. JCO
22: 2654-2661
[Abstract][Full Text]
Advani, R., Rosenberg, S. A., Horning, S. J.
(2004). Stage I and II Follicular Non-Hodgkin's Lymphoma: Long-Term Follow-Up of No Initial Therapy. JCO
22: 1454-1459
[Abstract][Full Text]
Davies, A.J., Rohatiner, A.Z.S., Howell, S., Britton, K.E., Owens, S.E., Micallef, I.N., Deakin, D.P., Carrington, B.M., Lawrance, J.A., Vinnicombe, S., Mather, S.J., Clayton, J., Foley, R., Jan, H., Kroll, S., Harris, M., Amess, J., Norton, A.J., Lister, T.A., Radford, J.A.
(2004). Tositumomab and Iodine I 131 Tositumomab for Recurrent Indolent and Transformed B-Cell Non-Hodgkin's Lymphoma. JCO
22: 1469-1479
[Abstract][Full Text]
Gopal, A. K., Gooley, T. A., Maloney, D. G., Petersdorf, S. H., Eary, J. F., Rajendran, J. G., Bush, S. A., Durack, L. D., Golden, J., Martin, P. J., Matthews, D. C., Appelbaum, F. R., Bernstein, I. D., Press, O. W.
(2003). High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood
102: 2351-2357
[Abstract][Full Text]
Akasaka, T., Lossos, I. S., Levy, R.
(2003). BCL6 gene translocation in follicular lymphoma: a harbinger of eventual transformation to diffuse aggressive lymphoma. Blood
102: 1443-1448
[Abstract][Full Text]
Hiddemann, W.
(2003). ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Oncol
14: 1163-1164
[Full Text]
Elenitoba-Johnson, K. S. J., Jenson, S. D., Abbott, R. T., Palais, R. A., Bohling, S. D., Lin, Z., Tripp, S., Shami, P. J., Wang, L. Y., Coupland, R. W., Buckstein, R., Perez-Ordonez, B., Perkins, S. L., Dube, I. D., Lim, M. S.
(2003). Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy. Proc. Natl. Acad. Sci. USA
100: 7259-7264
[Abstract][Full Text]
Martinez-Climent, J. A., Alizadeh, A. A., Segraves, R., Blesa, D., Rubio-Moscardo, F., Albertson, D. G., Garcia-Conde, J., Dyer, M. J. S., Levy, R., Pinkel, D., Lossos, I. S.
(2003). Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. Blood
101: 3109-3117
[Abstract][Full Text]
Zucca, E., Conconi, A., Pedrinis, E., Cortelazzo, S., Motta, T., Gospodarowicz, M. K., Patterson, B. J., Ferreri, A. J. M., Ponzoni, M., Devizzi, L., Giardini, R., Pinotti, G., Capella, C., Zinzani, P. L., Pileri, S., Lopez-Guillermo, A., Campo, E., Ambrosetti, A., Baldini, L., Cavalli, F.
(2003). Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood
101: 2489-2495
[Abstract][Full Text]
Peterson, B. A., Petroni, G. R., Frizzera, G., Barcos, M., Bloomfield, C. D., Nissen, N. I., Hurd, D. D., Henderson, E. S., Sartiano, G. P., Johnson, J. L., Holland, J. F., Gottlieb, A. J.
(2003). Prolonged Single-Agent Versus Combination Chemotherapy in Indolent Follicular Lymphomas: A Study of the Cancer and Leukemia Group B. JCO
21: 5-15
[Abstract][Full Text]
Klasa, R. J., Meyer, R. M., Shustik, C., Sawka, C. A., Smith, A., Guevin, R., Maksymiuk, A., Rubinger, M., Samosh, M., Laplante, S., Grenier, J.-F.
(2002). Randomized Phase III Study of Fludarabine Phosphate Versus Cyclophosphamide, Vincristine, and Prednisone in Patients With Recurrent Low-Grade Non-Hodgkin's Lymphoma Previously Treated With an Alkylating Agent or Alkylator-Containing Regimen. JCO
20: 4649-4654
[Abstract][Full Text]
Phanish, M K, Owen, A, Parry, D H
(2002). Spontaneous regression of acquired C1 esterase inhibitor deficiency associated with splenic marginal zone lymphoma presenting with recurrent angio-oedema. J. Clin. Pathol.
55: 789-790
[Abstract][Full Text]
Lossos, I. S., Alizadeh, A. A., Diehn, M., Warnke, R., Thorstenson, Y., Oefner, P. J., Brown, P. O., Botstein, D., Levy, R.
(2002). Transformation of follicular lymphoma to diffuse large-cell lymphoma: Alternative patterns with increased or decreased expression of c-myc and its regulated genes. Proc. Natl. Acad. Sci. USA
99: 8886-8891
[Abstract][Full Text]
McLaughlin, P.
(2002). Progress and Promise in the Treatment of Indolent Lymphomas. The Oncologist
7: 217-225
[Abstract][Full Text]
Montoto, S., Lopez-Guillermo, A., Ferrer, A., Camos, M., Alvarez-Larran, A., Bosch, F., Blade, J., Cervantes, F., Esteve, J., Cobo, F., Colomer, D., Campo, E., Montserrat, E.
(2002). Survival after progression in patients with follicular lymphoma: analysis of prognostic factors. Ann Oncol
13: 523-530
[Abstract][Full Text]
Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., Wahl, R. L., Knox, S. J., Vose, J. M.
(2001). Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. JCO
19: 3918-3928
[Abstract][Full Text]
van Kemenade, F. J., Raaphorst, F. M., Blokzijl, T., Fieret, E., Hamer, K. M., Satijn, D. P. E., Otte, A. P., Meijer, C. J. L. M.
(2001). Coexpression of BMI-1 and EZH2 polycomb-group proteins is associated with cycling cells and degree of malignancy in B-cell non-Hodgkin lymphoma. Blood
97: 3896-3901
[Abstract][Full Text]
Williams, C. D., Harrison, C. N., Lister, T. A., Norton, A. J., Blystad, A. K., Coiffier, B., Taghipour, G., Schmitz, N., Goldstone, A. H.
(2001). High-Dose Therapy and Autologous Stem-Cell Support for Chemosensitive Transformed Low-Grade Follicular Non-Hodgkin's Lymphoma: A Case-Matched Study From the European Bone Marrow Transplant Registry. JCO
19: 727-735
[Abstract][Full Text]
Horning, S. J., Negrin, R. S., Hoppe, R. T., Rosenberg, S. A., Chao, N. J., Long, G. D., Brown, B. W., Blume, K. G.
(2001). High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial. Blood
97: 404-409
[Abstract][Full Text]
Lossos, I. S., Levy, R.
(2000). Higher-grade transformation of follicle center lymphoma is associated with somatic mutation of the 5' noncoding regulatory region of the BCL-6 gene. Blood
96: 635-639
[Abstract][Full Text]
Corcione, A., Ottonello, L., Tortolina, G., Facchetti, P., Airoldi, I., Guglielmino, R., Dadati, P., Truini, M., Sozzani, S., Dallegri, F., Pistoia, V.
(2000). Stromal Cell-Derived Factor-1 as a Chemoattractant for Follicular Center Lymphoma B Cells. JNCI J Natl Cancer Inst
92: 628-635
[Abstract][Full Text]
Li, L., Zhang, X., Kovacic, S., Long, A. J., Bourque, K., Wood, C. R., Choi, Y. S.
(2000). Identification of a Human Follicular Dendritic Cell Molecule That Stimulates Germinal Center B Cell Growth. J. Exp. Med.
191: 1077-1084
[Abstract][Full Text]
Vose, J. M., Wahl, R. L., Saleh, M., Rohatiner, A. Z., Knox, S. J., Radford, J. A., Zelenetz, A. D., Tidmarsh, G. F., Stagg, R. J., Kaminski, M. S.
(2000). Multicenter Phase II Study of Iodine-131 Tositumomab for Chemotherapy-Relapsed/Refractory Low-Grade and Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas. JCO
18: 1316-1323
[Abstract][Full Text]
Hochster, H. S., Oken, M. M., Winter, J. N., Gordon, L. I., Raphael, B. G., Bennett, J. M., Cassileth, P. A.
(2000). Phase I Study of Fludarabine Plus Cyclophosphamide in Patients With Previously Untreated Low-Grade Lymphoma: Results and and Long-Term Follow-Up--A Report From the Eastern Cooperative Oncology Group. JCO
18: 987-987
[Abstract][Full Text]
Zinzani, P. L., Magagnoli, M., Moretti, L., De Renzo, A., Battista, R., Zaccaria, A., Guardigni, L., Mazza, P., Marra, R., Ronconi, F., Lauta, V. M., Bendandi, M., Gherlinzoni, F., Gentilini, P., Ciccone, F., Cellini, C., Stefoni, V., Ricciuti, F., Gobbi, M., Tura, S.
(2000). Randomized Trial of Fludarabine Versus Fludarabine and Idarubicin as Frontline Treatment in Patients With Indolent or Mantle-Cell Lymphoma. JCO
18: 773-773
[Abstract][Full Text]
Apostolidis, J., Gupta, R. K., Grenzelias, D., Johnson, P. W. M., Pappa, V. I., Summers, K. E., Salam, A., Adams, K., Norton, A. J., Amess, J. A. L., Matthews, J., Bradburn, M., Lister, T. A., Rohatiner, A. Z. S.
(2000). High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up. JCO
18: 527-527
[Abstract][Full Text]
Federico, M., Vitolo, U., Zinzani, P. L., Chisesi, T., Clo, V., Bellesi, G., Magagnoli, M., Liberati, M., Boccomini, C., Niscola, P., Pavone, V., Cuneo, A., Santini, G., Brugiatelli, M., Baldini, L., Rigacci, L., Resegotti, L.
(2000). Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Blood
95: 783-789
[Abstract][Full Text]
Cabanillas, F., Horning, S., Kaminski, M., Champlin, R.
(2000). Managing Indolent Lymphomas in Relapse: Working Our Way Through a Plethora of Options. ASH Education Book
2000: 166-179
[Abstract][Full Text]
Freedman, A. S., Neuberg, D., Mauch, P., Soiffer, R. J., Anderson, K. C., Fisher, D. C., Schlossman, R., Alyea, E. P., Takvorian, T., Jallow, H., Kuhlman, C., Ritz, J., Nadler, L. M., Gribben, J. G.
(1999). Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. Blood
94: 3325-3333
[Abstract][Full Text]
Diehl, V., Sextro, M., Franklin, J., Hansmann, M.-L., Harris, N., Jaffe, E., Poppema, S., Harris, M., Franssila, K., van Krieken, J., Marafioti, T., Anagnostopoulos, I., Stein, H.
(1999). Clinical Presentation, Course, and Prognostic Factors in Lymphocyte-Predominant Hodgkin's Disease and Lymphocyte-Rich Classical Hodgkin's Disease: Report From the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. JCO
17: 776-776
[Abstract][Full Text]
Mounter, P J, Lennard, A L
(1999). Classic diseases revisited: Management of non-Hodgkin's lymphomas. Postgrad. Med. J.
75: 2-6
[Abstract][Full Text]
Ellison, N. M.
(1998). Palliative chemotherapy. AM J HOSP PALLIAT CARE
15: 93-103
Solal-Celigny, P., Lepage, E., Brousse, N., Reyes, F., Haioun, C., Leporrier, M., Peuchmaur, M., Bosly, A., Parlier, Y., Brice, P., Coiffier, B., Gisselbrecht, C., The Groupe d'Etude des Lymphomes de l'Adulte,
(1993). Recombinant Interferon Alfa-2b Combined with a Regimen Containing Doxorubicin in Patients with Advanced Follicular Lymphoma. NEJM
329: 1608-1614
[Abstract][Full Text]
Previous
